# Bio-Rad Laboratories, Inc. (BIO) stock price

URL: https://funkfolio.com/stock/BIO

> Bio-Rad Laboratories, Inc. (BIO) trades at $358.19, is worth $9.63B, is priced at 9.5× earnings and scores 38/100. Valuation, financials and signals.

---

## Bio-Rad Laboratories, Inc. (BIO)

Bio-Rad Laboratories, Inc. (BIO) is a healthcare company (medical devices) based in the United States. The share price is $358.19, down 0.57% on the day, which values the company at $9.63B. Price as of 17 Nov 2026, 23:20 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $358.19 −0.57% today
- **Market value:** $9.63B
- **P/E ratio:** 9.5× last 12 months
- **Forward P/E:** 36.2×
- **Funk Score:** 38/100
- **Against its own history:** Below its usual price usual price $465.05
- **200-week average:** $325.58 10% above
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 23:20 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Bio-Rad Laboratories, Inc. in more detail

BIO trades at 9.5× its last twelve months' earnings, 36.2× next year's expected earnings, 3.7× sales. Measured against its own history, the price is 23% below what its usual multiples would imply ($465.05) — below its usual price. It sits 10% above its 200-week average of $325.58.

Over the last five fiscal years Bio-Rad Laboratories, Inc. has compounded revenue 0.3% a year, earnings per share -26.1% a year, free cash flow -4.7% a year. Its Funk Score is 38 out of 100 (financial strength 5.4, profitability 3.3, growth 1.1, value 5.2, each out of 10).

In its favour: Altman Z in the safe zone; Share count keeps falling. Worth checking: Low return on invested capital.

3 of the superinvestors tracked here hold BIO, including John Rogers (3.1% of the portfolio), Matthew McLennan (1.5% of the portfolio), Steven Romick (1.2% of the portfolio).

### Superinvestors holding BIO

3 of the investors tracked here report a position in their latest 13F filing.

- [John Rogers Ariel Investments](https://funkfolio.com/gurus/john-rogers) 3.10% of portfolio · $298.1M · trimmed · Q3 2026
- [Matthew McLennan First Eagle Investment Management](https://funkfolio.com/gurus/first-eagle) 1.46% of portfolio · $927.5M · trimmed · Q3 2026
- [Steven Romick First Pacific Advisors (FPA)](https://funkfolio.com/gurus/steven-romick) 1.21% of portfolio · $101.6M · trimmed · Q3 2026

### Health Care companies of similar size

- [Bio-Techne TECH](https://funkfolio.com/stock/TECH)
- [BioMarin Pharmaceutical BMRN](https://funkfolio.com/stock/BMRN)
- [Avantor AVTR](https://funkfolio.com/stock/AVTR)
- [Ensign Group ENSG](https://funkfolio.com/stock/ENSG)
- [Vaxcyte PCVX](https://funkfolio.com/stock/PCVX)
- [Molina Healthcare MOH](https://funkfolio.com/stock/MOH)
- [Spyre Therapeutics SYRE](https://funkfolio.com/stock/SYRE)
- [Qiagen QGEN](https://funkfolio.com/stock/QGEN)
- [Insulet PODD](https://funkfolio.com/stock/PODD)
- [Bruker BRKR](https://funkfolio.com/stock/BRKR)
- [Globus Medical GMED](https://funkfolio.com/stock/GMED)
- [Madrigal Pharmaceuticals MDGL](https://funkfolio.com/stock/MDGL)

Side by side: [BIO vs PCVX (Bio-Rad Laboratories, Inc. vs Vaxcyte)](https://funkfolio.com/compare/bio-vs-pcvx) [BIO vs MOH (Bio-Rad Laboratories, Inc. vs Molina Healthcare)](https://funkfolio.com/compare/bio-vs-moh) [BIO vs ENSG (Bio-Rad Laboratories, Inc. vs Ensign Group)](https://funkfolio.com/compare/bio-vs-ensg) [BIO vs SYRE (Bio-Rad Laboratories, Inc. vs Spyre Therapeutics)](https://funkfolio.com/compare/bio-vs-syre) [BIO vs QGEN (Bio-Rad Laboratories, Inc. vs Qiagen)](https://funkfolio.com/compare/bio-vs-qgen)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in the United States](https://funkfolio.com/companies/country/united-states) [All stocks A–Z](https://funkfolio.com/stocks)

### Bio-Rad Laboratories, Inc. (BIO): questions and answers

**What is BIO's P/E ratio?**

Bio-Rad Laboratories, Inc. trades at 9.5× its last twelve months' earnings and 36.2× next year's expected earnings. At its fiscal year-ends over the past 15 years the P/E ranged from 4.6× to 207.1×, with a median of 18.5×.

**What is BIO's PEG ratio?**

Bio-Rad Laboratories, Inc.'s PEG ratio is 4.01 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

**What is Bio-Rad Laboratories, Inc.'s market cap?**

Bio-Rad Laboratories, Inc. is valued at $9.63B at a share price of $358.19.

**Is BIO overvalued or undervalued?**

Against its own history, BIO is below its usual price: the price is 23% below the $465.05 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is BIO above its 200-week moving average?**

Yes. BIO is 10.0% above its 200-week average of $325.58. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Bio-Rad Laboratories, Inc. growing?**

Over the last five fiscal years Bio-Rad Laboratories, Inc.'s revenue grew 0.3% a year and its earnings per share -26.1% a year; over ten years revenue grew 2.5% a year.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Bio-Rad Laboratories, Inc. (BIO) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/BIO

Underlying data: Yahoo Finance; company filings with the SEC.
